J Periodontol:局部注射0.5%阿奇霉素辅助治疗慢性牙周炎合并2型糖尿病

2017-11-24 MedSci MedSci原创

几项流行病学研究发现2型糖尿病患者牙周炎的发生率更高。最近的研究发现,局部应用抗菌剂局可改善牙周健康。本研究旨在讨论龈下给药阿奇霉素(AZM; 0.5%浓度)作为辅助治疗2型糖尿病患者慢性牙周炎的疗效的效果。

几项流行病学研究发现2型糖尿病患者牙周炎的发生率更高。最近的研究发现,局部应用抗菌剂局可改善牙周健康。本研究旨在讨论龈下给药阿奇霉素(AZM; 0.5%浓度)作为辅助治疗2型糖尿病患者慢性牙周炎的疗效的效果。

方法:63例患者分为两组:1)第1组:SRP +安慰剂凝胶; 2)第2组:SRP + 0.5%AZM。在治疗前和3,6和9个月时记录临床参数;包括改良的龈沟出血指数(mSBI),菌斑指数(PI),探诊深度(PD)和临床附着水平(CAL)。

结果:两种疗法都显着改善牙周炎症状。与第1 组相比,SRP + 0.5%AZM治疗组患者在9个月内PI, GI,mSBI和PD降低的更多,并且CAL增加(P <0.05)

结论:虽然两种治疗方法都有效,但0.5%AZM的辅助使用增强了临床结果。

原始出处:


版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1726897, encodeId=13121e268974d, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Sat Jan 27 21:08:00 CST 2018, time=2018-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1368637, encodeId=c291136863e5b, content=<a href='/topic/show?id=0e30535657b' target=_blank style='color:#2F92EE;'>#慢性牙周炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53565, encryptionId=0e30535657b, topicName=慢性牙周炎)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5c64275, createdName=piaojinhua, createdTime=Sun Nov 26 01:08:00 CST 2017, time=2017-11-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1405781, encodeId=22051405e815b, content=<a href='/topic/show?id=a5404e589d7' target=_blank style='color:#2F92EE;'>#局部#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47589, encryptionId=a5404e589d7, topicName=局部)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Sun Nov 26 01:08:00 CST 2017, time=2017-11-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1450710, encodeId=2a951450e1049, content=<a href='/topic/show?id=f0476e49582' target=_blank style='color:#2F92EE;'>#牙周#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67495, encryptionId=f0476e49582, topicName=牙周)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ab585558129, createdName=liuyong2982, createdTime=Sun Nov 26 01:08:00 CST 2017, time=2017-11-26, status=1, ipAttribution=)]
    2018-01-27 feather89
  2. [GetPortalCommentsPageByObjectIdResponse(id=1726897, encodeId=13121e268974d, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Sat Jan 27 21:08:00 CST 2018, time=2018-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1368637, encodeId=c291136863e5b, content=<a href='/topic/show?id=0e30535657b' target=_blank style='color:#2F92EE;'>#慢性牙周炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53565, encryptionId=0e30535657b, topicName=慢性牙周炎)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5c64275, createdName=piaojinhua, createdTime=Sun Nov 26 01:08:00 CST 2017, time=2017-11-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1405781, encodeId=22051405e815b, content=<a href='/topic/show?id=a5404e589d7' target=_blank style='color:#2F92EE;'>#局部#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47589, encryptionId=a5404e589d7, topicName=局部)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Sun Nov 26 01:08:00 CST 2017, time=2017-11-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1450710, encodeId=2a951450e1049, content=<a href='/topic/show?id=f0476e49582' target=_blank style='color:#2F92EE;'>#牙周#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67495, encryptionId=f0476e49582, topicName=牙周)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ab585558129, createdName=liuyong2982, createdTime=Sun Nov 26 01:08:00 CST 2017, time=2017-11-26, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1726897, encodeId=13121e268974d, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Sat Jan 27 21:08:00 CST 2018, time=2018-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1368637, encodeId=c291136863e5b, content=<a href='/topic/show?id=0e30535657b' target=_blank style='color:#2F92EE;'>#慢性牙周炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53565, encryptionId=0e30535657b, topicName=慢性牙周炎)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5c64275, createdName=piaojinhua, createdTime=Sun Nov 26 01:08:00 CST 2017, time=2017-11-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1405781, encodeId=22051405e815b, content=<a href='/topic/show?id=a5404e589d7' target=_blank style='color:#2F92EE;'>#局部#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47589, encryptionId=a5404e589d7, topicName=局部)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Sun Nov 26 01:08:00 CST 2017, time=2017-11-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1450710, encodeId=2a951450e1049, content=<a href='/topic/show?id=f0476e49582' target=_blank style='color:#2F92EE;'>#牙周#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67495, encryptionId=f0476e49582, topicName=牙周)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ab585558129, createdName=liuyong2982, createdTime=Sun Nov 26 01:08:00 CST 2017, time=2017-11-26, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1726897, encodeId=13121e268974d, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Sat Jan 27 21:08:00 CST 2018, time=2018-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1368637, encodeId=c291136863e5b, content=<a href='/topic/show?id=0e30535657b' target=_blank style='color:#2F92EE;'>#慢性牙周炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53565, encryptionId=0e30535657b, topicName=慢性牙周炎)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5c64275, createdName=piaojinhua, createdTime=Sun Nov 26 01:08:00 CST 2017, time=2017-11-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1405781, encodeId=22051405e815b, content=<a href='/topic/show?id=a5404e589d7' target=_blank style='color:#2F92EE;'>#局部#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47589, encryptionId=a5404e589d7, topicName=局部)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Sun Nov 26 01:08:00 CST 2017, time=2017-11-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1450710, encodeId=2a951450e1049, content=<a href='/topic/show?id=f0476e49582' target=_blank style='color:#2F92EE;'>#牙周#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67495, encryptionId=f0476e49582, topicName=牙周)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ab585558129, createdName=liuyong2982, createdTime=Sun Nov 26 01:08:00 CST 2017, time=2017-11-26, status=1, ipAttribution=)]

相关资讯

世界类风湿性关节炎疫苗进入人体试验,或能治愈类风湿!

近期,来自昆士兰大学的研究人员们带来了类风湿性关节炎的治疗新进展,研究人员们进行了治疗类风湿性关节炎的人体实验,这是一种类似疫苗的治疗方法,研究人员称其为“免疫疗法”,这种新方法目标疾病的根本原因,而不是仅仅是治疗炎症的症状。

FDA宣布将“扩大获取计划”扩展至罕见病患者

一项旨在挽救晚期肿瘤患者的同情用药计划,如今罕见病患者也可以适用。

总局明确豁免临床试验IVD试剂临床评价资料要求

继10月30日,国家食品药品监管总局发布第三批免于进行临床试验的医疗器械目录(以下简称“目录”),对37种第二类医疗器械、11种第三类医疗器械和116种体外诊断(IVD)试剂豁免进行临床试验后,日前,总局又发布《免于进行临床试验的体外诊断试剂临床评价资料基本要求(试行)》(以下简称《基本要求》),并于发布之日起施行。《基本要求》配合目录使用,用于指导注册申请人进行体外诊断试剂临床评价工作。这是总局

《免于进行临床试验的体外诊断试剂临床评价资料基本要求(试行)》解读

国家食品药品监督管理总局组织制定并于2017年11月3日发布了《免于进行临床试验的体外诊断试剂临床评价资料基本要求(试行)》,自发布之日起施行。

CLIN CANCER RES:Trebananib用于治疗儿童复发实体肿瘤及原发神经系统肿瘤的Ⅰ期临床试验结果

Trebananib是抑制血管生成素1和2的一线抗血管生成抗体。CLIN CANCER RES近期发表了一篇文章,报道了Trebananib用于治疗儿童肿瘤的Ⅰ期临床试验结果,包括剂量限制毒性(DLT)、推荐Ⅱ期试验剂量(RP2D)和药代动力学等。

临床试验中分析集定义与区别

在临床试验数据的统计分析中,哪些病人应当包括在内,另外一些病人不应当包括在内,这是分析试验结果时首先要考虑的问题,分析集应当在试验方案的统计部分加以明确说明。如果临床试验中所有随机化的病人都符合入组标准而没有一项符合排除标准,试验过程中一切都符合试验方案的要求,没有失访或任何数据缺失,则所有病例都可包括在分析集中。但实际上在临床试验中很难做到。那么,对于这些与方案有所违反的病例,或是在试验中途